High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: Pilot study

Medical and Pediatric Oncology

Volumn 27, Issue 6, 1996, Pages 534-539

  Pardo, N ^a,d   Marti F ^c   Fraga, G ^a   Illa, J ^b   Badell, I ^a   Peiro M ^c   Bertran, E ^c   Garcia J ^c   Rueda, F ^c   Cubells, J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL SANT JOAN DE DÉU   (Spain)

^c Institut de Recerca Oncologica   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

autologous bone marrow transplantation; interleukin 2; natural killer; neuroblastoma

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; INTERLEUKIN 2; MELPHALAN; TENIPOSIDE;

ANEMIA; ANOREXIA; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CASE REPORT; DRUG MEGADOSE; EOSINOPHILIA; FEVER; HEPATOMEGALY; HUMAN; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOCYTOSIS; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; NEUROBLASTOMA; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INFANT; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; NEUROBLASTOMA; PILOT PROJECTS; THORACIC NEOPLASMS; TRANSPLANTATION, AUTOLOGOUS;

EID: 10344265995     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-911X(199612)27:6<534::AID-MPO5>3.0.CO;2-M     Document Type: Article

References (40)

1. Hayes FA, Smith EI: Neuroblastoma. In Pizzo PA, Poplack DG (eds): "Principles and Practice of Pediatric Oncology." Philadelphia: J.B. Lippincott, 1989, pp. 607-622.
2. Evans AE, August CHS, Kamani N, Bunin N, Goldwein J, Ross AJ III, D'Angio GJ: Bone marrow transplantation for high risk neuroblastoma at the Children's Hospital of Philadelphia: An updata. Med Pediatr Oncol 23:323-327, 1994.
3. Garaventa A, Ladenstein R, Chauvin F, Lanino E, Philip I, Corciulo P, Brisigotti M, Favrot M, Dini G, Philip T: High dose chemotherapy with autologous bone marrow resuce in advanced stage IV neuroblastoma. Eur J Cancer 29A:487-491, 1993.
4. Duan DS, Farmer D, Rayner AA, Sadee W: Cytotoxicity of lymphokine-activated killer cells against human neuroblastoma cells. Modualation by neuroblast differentiation. Med Pediatr Oncol 18:339-344, 1990.
5. Clayberger C, Medeiros LJ, Link MP, Warnke RA, Wright A, Koller TD, Smith SD, Krensky AM: Absence of cell surface LFA-1 is a mechanism of scape from innumosurveillance. Lancet 2:533, 1987.
6. Sugimoto T, Horii Y, Hino T, Kemshaed ST, Kuroda H, Sawada T, Morioka H, Imanishi J, Inoko H: Differential susceptibility of HLA class II antigens induced by gamma-interferon in human neuroblastoma cell lines. Cancer Res 49:1824-1926, 1989.
7. Handgretinger R, Bruchelt G, kimming A, Dopfer R, Niethammer D, Truener J: In vitro induction of lymphokine-activated killer (LAK) activity in patients with neuroblastoma. Pediatr Hematol Oncol 6:307-317, 1988.
8. Favrot M, Floret D, Michon J, Negrier S, Bouffet E, Coze C, Gaspard M, Cochat P, Thiesse P, Andreu G, Costil J, Zucker JM, Bernard JL, Fridman WH, Mathiot C, Bijmann JT, Franks CR, Kremens B, Philip I, Philip T: A phase-II study adoptive immunotherapy with continous infusion of interleukin-2 in children with advanced neuroblastoma. A report on 11 cases. Cancer Treat Rev 16:129-142, 1989.
9. Castel VS, Badal MI, Bezanilla JLR, Herrero AD, LLombart AB, Ruiz JJ, Sanchez de Toledo J: Neuroblastoma. Resultados del protocolo N-I-87. An Esp Pediatr 38:471-476, 1993.
10. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer. Cancer 47:207-214, 1981.
11. Boyum A: Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest 97:77-79, 1968.
12. Davidson WF: Cellular requirements for the induction of cytotoxic T cells in vitro. Immunol Rev 35:263-265, 1977.
13. Martí F, Miralles A, Peiró M, Amill B, Dalmases C, Piñol G, Rueda F, García J: Differential effect of cryopreservation on natural killer and lymphokine activated killer activities. Transfusion 33:651, 1993.
14. Heney CS: Quantitation of the cell mediated response. The number of cytolytically active mouse lymphoid cells induced by immunization with allogeneic mastocytoma cells. J Immunol 107:1551-1554, 1971.
15. Gerson JM, Herberman RB: Systemic and in situ natural killer activity in patients with neuroblastoma. In Evans AE (ed): "Advances Neuroblastoma Research." New York: Raven Press, 1980, pp. 251-259.
16. Chien CH, Hsieh KH: Interleukin-2 immunotherapy in children. Pediatrics 86:937-943, 1990.
17. Rossi AR, Pericle F, Rashleigh S, Janiec J, Djeu JY: Lysis of neuroblastoma cell lines by human natural killer cells activated by Interleukin-2 and Interleukin-12. Blood 83:1323-1328, 1994.
18. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White MS: Experience with the use of high-sode interleukin-2 in the treatment of 625 cancer patients. Ann Surg 210:474-485, 1986.
19. Nasr S, McKolanis J, Pais R, Findley H, Hnath R, Waldrep K, Ragab AH: A phase I study of interleukin-2 in children with cancer and evaluation of clinical and immunologic status during therapy. Cancer 64:783-788, 1989.
20. Berthold F, Himmelmann U, Pohl U: Natural interleukin-2 and lymphokine activated killer cells in the treatment of neuroblastoma in vitro and in vivo. Adv Neuroblastoma Res 3:417-421, 1991.
21. Whittington R, Faulds D: Interleukin-2. A reveiw of its pharmacological properties and therapeutic use in patients with cancer. Drugs 46:446-514, 1993.
22. Foreman NK, Rill DR, Coustan-Smith E, Douglas EC, Brenner MK: Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease erediction. Br J Cancer 67:933-939, 1993.
23. Favrot M, Michon J, Bouffet E, Negirer S, Cochat P, Floret D, Gaspard M, Coze C, Andreu G, Franks CR, Philip I, Philip T: rIL-2 Immunotherapy for 19 Children with advanced metastatic neuroblastoma. In Freund, Link, Welte (eds): "Cytokines in hemopoiesis, oncology and AIDS." Heidelberg: Springer-Verlag, 1990, pp. 684-690.
24. Negrier S, Michon J, Floret D, Bouffet E, Gentet JC, Philip E, Cochat P, Stamm D, Costil J, Gaspard M, Andreu G, Palmer P, Franks CR, Zucker JM, Bernard JL, Fridman WH, Favrot M, Philip T: Interleukin-2 and lymphokine-activated killer cells in 15 children with advanced metastatic neuroblastoma. J Clin Oncol 9:1363-1370, 1991.
25. Maraninchi D, Blaise D, Olive D, Attal M, Gaspard MH, Boule D, Jasmin C, Pourreau C, Palmer P, Negrier S, Philip I: Interleukin-2 after autologous bone marrow transplantation (ABMT): A pilot study of late administration, 2-3 months post ABMT. In Freund, Link, Welte (eds): "Cytokines in Hemopoiesis, Oncology and AIDS." Heidelberg: Springer-Verlag, 1990, pp. 691-697.
26. Dopfer R, Handgretinger R, Klingebiel T, Reuland P, Eppinger T, Scheel-Walter H, Ehninger G, Niethammer D: IL-2 treatment in a patient with stage IV neuroblastoma after bone marrow transplantation. In Freund, Link, Welte (eds) "Cytokines in Hemopoiesis, Oncology and AIDS." Heidelberg: Springer-Verlag, 1990, pp. 699-705.
27. Chien CH, Hsieh KH: Interleukin-2 immunotherapy in children. Pediatrics 86:937-943, 1990.
28. Michon J, Negrier S, Coze C, Zucker JM, Frappaz D, Oskam R, Palmer P, Frank CR, Bouffet E, Floret D, Favort M, Fridman WH, Philip T. Administration of high dose recombinant interleukin 2 after autologous bone marrow transplantation (ABMT) in 23 patients with metastatic neuroblastoma: Abstract 4204, 19th Meeting of the EBMT 1993; Garsmisch, Germany.
29. Ravaud A, Negrier S, Mercatello A, Cany L, Coronel B, Ranchere JY, Bécouarn Y, Bui BN, Philip T: Effects secondaires de l'interleukine 2. Bull Cancer 78:989-1005, 1991.
30. Mercatello A, Hadj-Aïssa A, Negrier S, Tognet E, Bret M, Favrot M, Poret N, Philip T, Moscovtchenko JF: Modifications rénales au cours de l'immunothérapie par interleukine 2. In: "Réanimation et Médecine d'Urgence." Paris: Expansion Scientifique Française, 1991, pp. 479-489.
31. Webb DE, Austin III HA, Belldegrun A, Vaughan E, Linehan WM, Rosenberg SA: Metabolic and renal effects of interleukin-2 immunotherapy of advanced cancer. Clin Nephrol 30:141-145, 1988.
32. Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI: Dermatologic changes associated with interteukin-2 administration. JAMA 258:1624-1629, 1987.
33. Ettinghausen SE, Puri RK, Rosenberg SA: Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice. J Natl Cancer Inst 80:177-188, 1988.
34. Rosenstein M, Ettinghausen SE, Rosenberg SA: Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol 137:1735-1742, 1986.
35. Caraceni A, Martini C, Belli F, Mascharoni L, Rivoltini L, Arienti F, Cacinelli N: Neuropsychological and neurophysiological assessment of the central effects of interleukin-2 administration. Eur J Cancer 29:1266-1269, 1993.
36. Blaise D, Olive D, Stoppa AM, Viens P, Pourreau C, Lopez M, Attal M, Jasmin C, Monges G, Mawas C, Mannoni P, Palmer P, Franks C, Philip T, Maraninchi D: Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 76:1092-1097, 1990.
37. Klempner MS, Noring R, Mier JW, Atkins MB: An acquired chemotactic detect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med. 322:959-965, 1990.
38. Snydman DR, Sullivan B, Gill M, Gould JA, Parkinson DR, Atkins MB: Nosocomial sepsis associated with interleukin-2. Ann Intern Med 112:102-107, 1990.
39. Pockaj BA, Topalian SL, Steinberg SM, White DE, Rosenberg SA: Infectious complications associated with interleukin-2 administration: A retrospective review of 935 treatment courses. J Clin Oncol 11:136-147, 1993.
40. Mier JW, Vachino G, Klempner MS., Aronson FA, Noring R, Smith S, Brandon EP, Laird W, Atkins MB: Inhibition of interleukin-2 induced tumor necrosis factor release by dexamethasone: Prevention of an acquired neutrophil chemotaxis defect and differential suppression on interleukin-2-associated side effects. Blood 76:1933-1940, 1990.